578 related articles for article (PubMed ID: 30611457)
21. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
[TBL] [Abstract][Full Text] [Related]
22. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
[TBL] [Abstract][Full Text] [Related]
24. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
25. US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials: A Systematic Review and Meta-analysis.
Razavi M; Glasziou P; Klocksieben FA; Ioannidis JPA; Chalmers I; Djulbegovic B
JAMA Netw Open; 2019 Sep; 2(9):e1911111. PubMed ID: 31509209
[TBL] [Abstract][Full Text] [Related]
26. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
[TBL] [Abstract][Full Text] [Related]
27. Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis.
Zeitoun JD; Ross JS; Atal I; Vivot A; Downing NS; Baron G; Ravaud P
Clin Pharmacol Ther; 2018 Nov; 104(5):1000-1007. PubMed ID: 29377075
[TBL] [Abstract][Full Text] [Related]
28. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
[TBL] [Abstract][Full Text] [Related]
32. The Impact of Variability in Patient Exposure During Premarket Clinical Development on Postmarket Safety Outcomes.
Cherkaoui S; Pinnow E; Bulatao I; Day B; Kalaria M; Brajovic S; Dal Pan G
Clin Pharmacol Ther; 2021 Dec; 110(6):1512-1525. PubMed ID: 34057195
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Data Supporting the Efficacy of New Antibiotics for Treating Infections Caused by Multidrug-resistant Bacteria.
Yahav D; Tau N; Shepshelovich D
Clin Infect Dis; 2021 Jun; 72(11):1968-1974. PubMed ID: 32337578
[TBL] [Abstract][Full Text] [Related]
34. Postmarketing trials and pediatric device approvals.
Hwang TJ; Kesselheim AS; Bourgeois FT
Pediatrics; 2014 May; 133(5):e1197-202. PubMed ID: 24733871
[TBL] [Abstract][Full Text] [Related]
35. U.S. Food and Drug Administration drug approval: slow advances in obstetric care in the United States.
Wing DA; Powers B; Hickok D
Obstet Gynecol; 2010 Apr; 115(4):825-833. PubMed ID: 20308845
[TBL] [Abstract][Full Text] [Related]
36. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Wallach JD; Ross JS; Naci H
Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
[TBL] [Abstract][Full Text] [Related]
37. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
Wallach JD; Luxkaranayagam AT; Dhruva SS; Miller JE; Ross JS
BMC Med; 2019 Jun; 17(1):117. PubMed ID: 31203816
[TBL] [Abstract][Full Text] [Related]
38. Accelerated approval of drugs: ethics versus efficacy.
Chary KV; Pandian K
Indian J Med Ethics; 2017; 2(4):244-247. PubMed ID: 28661403
[TBL] [Abstract][Full Text] [Related]
39. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
[TBL] [Abstract][Full Text] [Related]
40. Publication of clinical trials supporting successful new drug applications: a literature analysis.
Lee K; Bacchetti P; Sim I
PLoS Med; 2008 Sep; 5(9):e191. PubMed ID: 18816163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
